Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

10 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Cancer NCT00756847

- 10/11/17 - 1 formulario, 2 itemgroups, 20 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00756847

Eligibility Carcinoma, Non-Small-Cell Lung NCT00001499

- 17/11/21 - 1 formulario, 1 itemgroup, 20 items, 1 idioma
Itemgroup: Criteria
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00001499

Eligibility Lung Cancer NCT00003053

- 20/9/21 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Criteria
Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed; ODM derived from: https://clinicaltrials.gov/show/NCT00003053

Eligibility Lung Cancer NCT00193310

- 19/1/16 - 1 formulario, 2 itemgroups, 16 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00193310

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Screening - Prior an Concomitant Medication; Telephone Randomisation

- 18/4/21 - 1 formulario, 4 itemgroups, 13 items, 1 idioma
Itemgroups: Administrative, Prior and Concomitant Medication, Prior and Concomitant Medication , Telephone Randomisation
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Eligibility Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck NCT01059643

- 3/9/18 - 1 formulario, 2 itemgroups, 13 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT01059643 Sponsor: Eli Lilly and Company Information provided by (Responsible Party): Eli Lilly and Company

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Screening - Prior Cancer and Non-Cancer related surgical procedures; Concomitant Medications; Tumor Tissue Biopsy Sample; Tumor Tissue Biopsy Sample Details

- 16/5/19 - 1 formulario, 5 itemgroups, 30 items, 1 idioma
Itemgroups: Date of visit/ assessment, Prior Cancer and Non-Cancer related surgical procedures, Concomitant Medications, Tumor Tissue Biopsy Sample, Tumor Tissue Biopsy Sample Details
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Eligibility Non Small Cell Lung Cancer (NSCLC) DRKS00005552 NCT00684385 - Eligibility Non Small Cell Lung Cancer (NSCLC) NCT00684385

- 30/7/16 - 1 formulario, 2 itemgroups, 8 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck; ODM derived from: https://clinicaltrials.gov/show/NCT00684385

Eligibility Carcinoma NCT00243347

- 25/1/17 - 1 formulario, 2 itemgroups, 13 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00243347

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Screening - Subject Identification; Demography; Disease Characteristics; Status at Screening; Anti-Cancer Therapy; Anti-Cancer Radiotherapy; Medical Conditions

- 15/3/21 - 1 formulario, 12 itemgroups, 64 items, 1 idioma
Itemgroups: Inform Screening, Subject number, Date of Visit/ Assessment, Local Laboratories, Subject identification, Demography, Disease Characteristics, Metastatic Disease, Status at Screening, Anti-Cancer Therapy, Anti-Cancer Therapy , Medical Conditions
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial